Libya vs Myanmar: Cause of death, by non-communicable diseases, ages 60+, male
Libya
67.7%
in 2021
Myanmar
67.7%
in 2021
Libya rank
98th
Myanmar rank
99th
Cause of death, by non-communicable diseases, ages 60+, male over time
- Libya
- Myanmar
How they compare
Libya currently reports 67.7% against 67.7% in Myanmar, a difference of 0.0%.
The two have swapped places 2 times across 6 shared years of data; in 2000 it was Libya ahead.
Libya ranks 98th and Myanmar ranks 99th of 185 countries.
Across the 3 decades both report, Libya averaged higher in 2 and Myanmar in 1.
Head to head by decade
| Decade | Libya | Myanmar | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 88.8% | 66.5% | 22.3% | Libya |
| 2010s | 89.7% | 78.3% | 11.4% | Libya |
| 2020s | 73.6% | 74.4% | 0.8% | Myanmar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher cause of death, by non-communicable diseases, ages 60+, male, Libya or Myanmar?
- Libya, at 67.7% against 67.7% in Myanmar as of 2021.
- What is the difference in cause of death, by non-communicable diseases, ages 60+, male between Libya and Myanmar?
- 0.0%, with Libya ahead.
- How many years of comparable data are there for Libya and Myanmar?
- 6 years are reported by both, from 2000 to 2021.
- How do Libya and Myanmar rank globally for cause of death, by non-communicable diseases, ages 60+, male?
- Libya ranks 98th and Myanmar ranks 99th of 185 countries.
- Where does this data come from?
- Global Health Estimates, World Health Organization (WHO), published as Cause of death, by non-communicable diseases, ages 60+, male (% of total male deaths ages 60+). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Number of male deaths ages 60+ due to non-communicable diseases divided by number of all male deaths ages 60+, expressed by percentage. Non-Communicable diseases include cancer, diabetes mellitus, cardiovascular diseases, digestive diseases, skin diseases, musculoskeletal diseases, and congenital anomalies.